Precision oncology is undergoing a structural shift — not from a single drug breakthrough, but from an entire treatment paradigm that fuses diagnostic imaging and targeted radiation into a single, personalized strategy. For adults navigating cancer risk or treatment decisions, this evolution matters because it challenges the one-size-fits-all model of oncological care and introduces therapies that can find and destroy tumor cells with molecular specificity.
Radiotheranostics pairs a diagnostic radiopharmaceutical — used to image where a specific molecular target is expressed — with a therapeutic counterpart that delivers radiation to those same sites. Two validated examples anchor the field: Lutetium-177-DOTATATE, approved for somatostatin-receptor-positive neuroendocrine tumors, and Lutetium-177-PSMA-617, approved for metastatic castration-resistant prostate cancer. Both were validated through randomized controlled trials, establishing an evidence base that is now driving the field away from empirical dosing. Emerging targets include fibroblast activation protein, which is expressed across tumor stroma in many solid cancers, potentially expanding radiotheranostics well beyond its current indications. Next-generation radionuclides — particularly targeted alpha-particle emitters — offer higher linear energy transfer and may prove more effective against micrometastatic disease, where beta-emitters have shown limitations. Ligand engineering advances, including multivalent constructs and half-life extension, are being developed to increase tumor retention without sacrificing tolerability.
This review arrives at a clinically meaningful inflection point. The convergence of AI-enabled dosimetry, voxel-level treatment planning, and expanding molecular targets suggests radiotheranostics could eventually become a platform technology applicable across multiple cancer types rather than a niche tool. However, the field faces real constraints: radiopharmaceutical manufacturing is complex and geographically limited, treatment access remains uneven, and most emerging targets lack the Phase III evidence supporting PSMA and somatostatin receptor therapies. The shift to individualized dosimetry — away from fixed activity dosing — is scientifically sound but operationally demanding. As a review article, this piece synthesizes existing knowledge rather than reporting new trial data, making it directionally important but not independently practice-changing. Still, it represents a credible map of where precision radiation medicine is heading over the next decade.